Saturday 17 October 2026
Export RGNX’s income statement to Excel — free account
REGENXBIO Inc.
RGNX Healthcare Biotechnology
REGENXBIO Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.4 million, up 104.5% from fiscal 2024. In the quarter to June 2026, revenue grew 405.7%, EPS grew 131.2% and free cash flow fell 26.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.93
0.23
−3.21%
Follow RGNX
REGENXBIO Inc. (RGNX) P/E ratio
REGENXBIO Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 45.1× (June 2018) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 11.1× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 13.2× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 45.1×
Ten-year median
0.0×
Current reading's percentile
82
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RGNX REGENXBIO Inc. | n/m |
| MNPR Monopar Therapeutics Inc. compare | n/m |
| NGNE Neurogene Inc. compare | n/m |
| ALT Altimmune, Inc. compare | n/m |
| CBIO Crescent Biopharma, Inc. compare | n/m |
| ENTX Entera Bio Ltd. compare | n/m |
| ALLO Allogene Therapeutics, Inc. compare | n/m |
| ARVN Arvinas, Inc. compare | 53.6× |
| YDES YD Bio Limited compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)